New antibody drug targets Hard-to-Treat cancers in early trial
Disease control
Recruiting now
This early-stage trial is testing an experimental drug called MOv18 IgE in people with advanced ovarian, endometrial, or triple-negative breast cancers that have a specific protein (folate receptor alpha) on their cells. The study has two parts: first, finding the safest dose, an…
Phase: PHASE1 • Sponsor: Epsilogen Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC